Your browser doesn't support javascript.
loading
Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
Deleye, Steven; Waldron, Ann-Marie; Verhaeghe, Jeroen; Bottelbergs, Astrid; Wyffels, Leonie; Van Broeck, Bianca; Langlois, Xavier; Schmidt, Mark; Stroobants, Sigrid; Staelens, Steven.
Afiliação
  • Deleye S; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
  • Waldron AM; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
  • Verhaeghe J; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
  • Bottelbergs A; Neuroscience Department, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Wyffels L; Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
  • Van Broeck B; Nuclear Medicine Department, University Hospital Antwerp, Antwerp, Belgium; and.
  • Langlois X; Neuroscience Department, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Schmidt M; Foundational Neuroscience Center, Abbvie, Cambridge, Massachusetts.
  • Stroobants S; Neuroscience Department, Janssen Pharmaceutica NV, Beerse, Belgium.
  • Staelens S; Nuclear Medicine Department, University Hospital Antwerp, Antwerp, Belgium; and.
J Nucl Med ; 58(12): 1977-1983, 2017 12.
Article em En | MEDLINE | ID: mdl-28611242
ABSTRACT
In this study, we investigated the effects of chronic administration of an inhibitor of the ß-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice.

Methods:

Wild-type (WT) and TG mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age. Outcome measures of brain metabolism, neuroinflammation, and amyloidpathology were obtained through small-animal PET imaging with 18F-FDG, 18F-peripheral benzodiazepine receptor (18F-PBR), and 18F-florbetapir (18F-AV45), respectively. Baseline scans were acquired at 6-7 wk of age and follow-up scans at 4, 7, and 12 mo. 18F-AV45 uptake was measured at 8 and 13 mo of age. After the final scans, histologic measures of amyloid-ß (4G8), microglia (ionized calcium binding adaptor molecule 1), astrocytes (glial fibrillary acidic protein), and neuronal nuclei were performed.

Results:

TG mice demonstrated significant age-associated increases in 18F-AV45 uptake. An effect of treatment was observed in the cortex (P = 0.0014), hippocampus (P = 0.0005), and thalamus (P < 0.0001). Histology confirmed reduction of amyloidpathology in TG-BACE mice. Regardless of treatment, TG mice demonstrated significantly lower 18F-FDG uptake than WT mice in the thalamus (P = 0.0004) and hippocampus (P = 0.0332). Neuronal nucleus staining was lower in both TG groups in the thalamus and cortex. 18F-PBR111 detected a significant age-related increase in TG mice (P < 0.0001) but did not detect the treatment-induced reduction in activated microglia as demonstrated by histology.

Conclusion:

Although 18F-FDG, 18F-PBR111, and 18F-AV45 all detected pathologic alterations between TG and WT mice, only 18F-AV45 could detect an effect of BACE inhibitor treatment. However, changes in WT binding of 18F-AV45 undermine the specificity of this effect.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Aspártico Endopeptidases / Secretases da Proteína Precursora do Amiloide / Doença de Alzheimer Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Aspártico Endopeptidases / Secretases da Proteína Precursora do Amiloide / Doença de Alzheimer Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article